Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Rating of “Moderate Buy” by Brokerages
Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) has earned an average recommendation of “Moderate Buy” from the nine research firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price objective […]
19 Sep 04:27 · The Cerbat Gem